The clinical trial focuses on patients with moderately to severely active ulcerative colitis (UC)

Your UC diagnosis must be confirmed at least 3 months before joining the study

Your condition will be evaluated using a modified Mayo score between 5 to 9, including an endoscopy examination

Your previous treatments must show inadequate response, loss of response, or intolerance to at least one conventional therapy, biologic therapy, or targeted small molecule therapy

If you are taking any of these medications, they must be at stable doses:

– Oral 5-aminosalicylates (stable for at least 2 weeks)

– Oral corticosteroids (20mg/day or less of prednisone, stable for at least 2 weeks)

– Budesonide (9mg/day, stable for at least 2 weeks)

– Beclomethasone dipropionate (5mg/day, stable for at least 2 weeks)

– Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate – stable for at least 12 weeks)

The study medication is called efavaleukin alfa

You will receive either the study medication or a placebo

The treatment period lasts for 12 weeks

At week 12, your condition will be evaluated for:

– Clinical remission (main goal)

– Clinical response

– Endoscopic examination results

– Symptoms improvement

– Colon tissue examination

Any side effects will be monitored throughout the study